These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

543 related items for PubMed ID: 25891777

  • 21. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
    Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink HK, Müller RP, Diehl V.
    N Engl J Med; 2010 Aug 12; 363(7):640-52. PubMed ID: 20818855
    [Abstract] [Full Text] [Related]

  • 22. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
    Straus DJ, Długosz-Danecka M, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Connors JM, Radford J, Munoz J, Kim WS, Advani R, Ansell SM, Younes A, Miao H, Liu R, Fenton K, Forero-Torres A, Gallamini A.
    Blood; 2020 Mar 05; 135(10):735-742. PubMed ID: 31945149
    [Abstract] [Full Text] [Related]

  • 23. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
    Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Müller M, Fätkenheuer G, Seidel E, Nickelsen M, Wolf T, Rieke A, Schürmann D, Schmidmaier R, Planker M, Alt J, Mosthaf F, Engert A, Arasteh K, Hoffmann C.
    J Clin Oncol; 2012 Nov 20; 30(33):4117-23. PubMed ID: 23045592
    [Abstract] [Full Text] [Related]

  • 24. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
    Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A.
    J Clin Oncol; 2010 Sep 20; 28(27):4199-206. PubMed ID: 20713848
    [Abstract] [Full Text] [Related]

  • 25. Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305).
    Ogura M, Itoh K, Kinoshita T, Fukuda H, Takenaka T, Ohtsu T, Kagami Y, Tobinai K, Okamoto M, Asaoku H, Sasaki T, Mikuni C, Hirano M, Chou T, Ohnishi K, Ohno H, Nasu K, Okabe K, Ikeda S, Nakamura S, Hotta T, Shimoyama M.
    Int J Hematol; 2010 Dec 20; 92(5):713-24. PubMed ID: 21076995
    [Abstract] [Full Text] [Related]

  • 26. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y, Shi YK, He XH, Feng FY, Zhou LQ, Gu DZ.
    Zhonghua Zhong Liu Za Zhi; 2008 Aug 20; 30(8):630-4. PubMed ID: 19102946
    [Abstract] [Full Text] [Related]

  • 27. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.
    Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, Horning SJ, Dar AR, Shustik C, Stewart DA, Crump M, Djurfeldt MS, Chen BE, Shepherd LE, NCIC Clinical Trials Group, Eastern Cooperative Oncology Group.
    N Engl J Med; 2012 Feb 02; 366(5):399-408. PubMed ID: 22149921
    [Abstract] [Full Text] [Related]

  • 28. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
    Diehl V, Fuchs M, GHSG.
    Transfus Apher Sci; 2007 Aug 02; 37(1):37-41. PubMed ID: 17714996
    [Abstract] [Full Text] [Related]

  • 29. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
    Castillo JJ, Bower M, Brühlmann J, Novak U, Furrer H, Tanaka PY, Besson C, Montoto S, Cwynarski K, Abramson JS, Dalia S, Bibas M, Connors JM, Furman M, Nguyen ML, Cooley TP, Beltran BE, Collins JA, Vose JM, Xicoy B, Ribera JM, HIV-Associated Hodgkin Lymphoma in the cART Era Study Group.
    Cancer; 2015 Feb 01; 121(3):423-31. PubMed ID: 25251326
    [Abstract] [Full Text] [Related]

  • 30. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era.
    Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M, Cwynarski K, Marcus R, de Vos J, Young AM, Tenant-Flowers M, Orkin C, Johnson M, Chilton D, Gribben JG, Bower M.
    J Clin Oncol; 2012 Nov 20; 30(33):4111-6. PubMed ID: 23045581
    [Abstract] [Full Text] [Related]

  • 31. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.
    Straus DJ, Długosz-Danecka M, Connors JM, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Munoz J, Lee HJ, Kim WS, Advani R, Ansell SM, Younes A, Gallamini A, Liu R, Little M, Fenton K, Fanale M, Radford J.
    Lancet Haematol; 2021 Jun 20; 8(6):e410-e421. PubMed ID: 34048680
    [Abstract] [Full Text] [Related]

  • 32. Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.
    Chand VK, Link BK, Ritchie JM, Shannon M, Wooldridge JE.
    Leuk Lymphoma; 2006 Apr 20; 47(4):657-63. PubMed ID: 16690524
    [Abstract] [Full Text] [Related]

  • 33. Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma.
    Ramchandren R, Advani RH, Ansell SM, Bartlett NL, Chen R, Connors JM, Feldman T, Forero-Torres A, Friedberg JW, Gopal AK, Gordon LI, Kuruvilla J, Savage KJ, Younes A, Engley G, Manley TJ, Fenton K, Straus DJ.
    Clin Cancer Res; 2019 Mar 15; 25(6):1718-1726. PubMed ID: 30617130
    [Abstract] [Full Text] [Related]

  • 34. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
    Souza EM, Baiocchi OC, Zanichelli MA, Alves AC, Oliveira JS.
    Ann Hematol; 2009 Jul 15; 88(7):633-7. PubMed ID: 18998131
    [Abstract] [Full Text] [Related]

  • 35. A randomized trial of brief treatment of early- stage Hodgkin lymphoma: Is it effective?
    Hamed RH, Anter AH, Awad IA.
    Hematol Oncol Stem Cell Ther; 2012 Jul 15; 5(1):36-41. PubMed ID: 22446609
    [Abstract] [Full Text] [Related]

  • 36. Outcomes in Patients with Classic Hodgkin Lymphoma Treated with ABVD: A Single-center Retrospective Study.
    Makiyama J, Imaizumi Y, Watanabe H, Fujioka M, Chiwata M, Kitanosono H, Nakashima J, Miyazaki Y, Yoshida S.
    Intern Med; 2021 Mar 01; 60(5):709-718. PubMed ID: 33087662
    [Abstract] [Full Text] [Related]

  • 37. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
    Pavlovsky S, Corrado C, Pavlovsky MA, Prates MV, Zoppegno L, Giunta M, Cerutti I, Palomino E, Pagani F, Lastiri F, Bar D, Bezares RF, Avila G.
    Clin Lymphoma Myeloma Leuk; 2010 Jun 01; 10(3):181-5. PubMed ID: 20511162
    [Abstract] [Full Text] [Related]

  • 38. Real-world evidence of ABVD-like regimens compared with ABVD in classical Hodgkin lymphoma: a 10-year study from China.
    Wen Q, Ge J, Lei Y, Zhang Y, Kong X, Wang W, Hou H, Wang Z, Qian S, Ding M, Dong M, Zhu L, Zhang M, Zhang X, Chen Q.
    J Cancer Res Clin Oncol; 2023 Jul 01; 149(7):3989-4003. PubMed ID: 36030432
    [Abstract] [Full Text] [Related]

  • 39. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
    Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M, Intergruppo Italiano Linfomi.
    J Clin Oncol; 2005 Dec 20; 23(36):9198-207. PubMed ID: 16172458
    [Abstract] [Full Text] [Related]

  • 40. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP.
    Santoro A, Viviani S, Villarreal CJ, Bonfante V, Delfino A, Valagussa P, Bonadonna G.
    Cancer Treat Rep; 1986 Mar 20; 70(3):343-8. PubMed ID: 2420444
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.